Overview Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults Status: Completed Trial end date: 2020-02-26 Target enrollment: Participant gender: Summary A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW032 and Xgeva® in healthy adults. Phase: Phase 1 Details Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.